Magnetic resonance imaging of angiogenesis in tumors;Imagerie par résonance magnétique de l'angiogenèse tumorale

Journal de Radiologie

Volumn 88, Issue 3 C1, 2007, Pages 331-338

  Huwart, L ^a   Michoux, N ^a   Van Beers, B E ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Angiogenesis; Perfusion MRI; Tumors

Indexed keywords

GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOMELITOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANGIOGENESIS; BLOOD OXYGENATION; DIFFUSION; HUMAN; HYPERCAPNIA; HYPEROXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MATHEMATICAL ANALYSIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; REVIEW; SIGNAL NOISE RATIO; TUMOR VASCULARIZATION;

EID: 34247173942     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(07)89829-5     Document Type: Short Survey

References (57)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.
3. Barentsz JO, Engelbrecht M, Jager GJ, Witjes JA, de LaRosette J, van Der Sanden BP, et al. Fast dynamic gadoliniumenhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999;10:295-304.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
5. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
6. Le Bas JF, Grand S, Krainik A, Lefournier V, Tropres I, Rémy C. IRM de perfusion des tumeurs cérébrales. J Radiol 2006;87:807-21.
7. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 1999;19:701-35.
8. Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR. Contrast agents in functional MR imaging. J Magn Reson Imaging 1997;7:47-55.
9. Fournier LS, Brasch RC. The role of blood pool contrast media in the study of tumor pathophysiology. In: Jackson A, Buckley DL, Parker GJM (eds). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin Heidelberg: Springer, 2005. p. 39-52.
10. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-24.
11. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000;34:148-55.
12. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 2001;218:365-74.
13. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001;3:143-53.
14. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
15. Turetschek K, Roberts TP, Floyd E, Preda A, Novikov V, Shames DM, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001;13:882-8.
16. Evelhoch JL. Consensus recommendations for acquisition of dynamic contrastenhanced MRI data in oncology. In: Jackson A, Buckley DL, Parker GJM (eds). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer, 2005. p. 109-114.
17. Perrin RL, Ivancevic MK, Kozerke S, Vallee JP. Comparative study of FAST gradient echo MRI sequences: phantom study. J Magn Reson Imaging 2004;20:1030-8.
18. Jackson A, Nicholson DA. Dynamic contrast-enhanced MR imaging in the liver. In: Jackson A, Buckley DL, Parker GJM (eds). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin Heidelberg: Springer, 2005. p. 239-261.
19. Gribbestad IS, Nilsen G, Fjosne HE, Kvinnsland S, Haugen OA, Rinck PA. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging 1994;4:477-80.
20. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7:564-74.
21. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76 Spec No 1:S60-80.
22. Gowland P, Mansfield P, Bullock P, Stehling M, Worthington B, Firth J. Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echoplanar imaging. Magn Reson Med 1992;26:241-58.
23. Freeman AJ, Gowland PA, Mansfield P. Optimization of the ultrafast Look-Locker echo-planar imaging T1 mapping sequence. Magn Reson Imaging 1998;16:765-72.
24. Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575-85.
25. Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of T1 measurement in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable flip angle fast lowangle shot. J Magn Reson Imaging 1999;9:163-71.
26. Ivancevic MK, Zimine I, Montet X, Hyacinthe JN, Lazeyras F, Foxall D, et al. Inflow effect correction in fast gradientecho perfusion imaging. Magn Reson Med 2003;50:885-91.
27. Peeters F, Annet L, Hermoye L, Van Beers BE. Inflow correction of hepatic perfusion measurements using T1-weighted, fast gradient-echo, contrast-enhanced MRI. Magn Reson Med 2004;51:710-7.
28. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-610.
29. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-67.
30. Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 1998;40:537-43.
31. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002;47:601-6.
32. Haroon HA, Buckley DL, Patankar TA, Dow GR, Rutherford SA, Baleriaux D, et al. A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 2004; 19:527-36.
33. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: II. Experimental validation. J Cereb Blood Flow Metab 1998;18:1378-85.
34. Jerosch-Herold M, Wilke N, Wang Y, Gong GR, Mansoor AM, Huang H, et al. Direct comparison of an intravascular and an extracellular contrast agent for quantification of myocardial perfusion. Cardiac MRI Group. Int J Card Imaging 1999;15:453-64.
35. Henderson E, Sykes J, Drost D, Weinmann HJ, Rutt BK, Lee TY. Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. J Magn Reson Imaging 2000;12:991-1003.
36. Buxton RB, Frank LR, Wong EC, Siewert B, Warach S, Edelman RR. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med 1998;40:383-96.
37. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523-32.
38. Boss A, Martirosian P, Schraml C, Clasen S, Fenchel M, Anastasiadis A, et al. Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas. Eur Radiol 2006;16:1226-36.
39. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497-505.
40. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005;237:492-9.
41. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001;14:156-63.
42. Leroy-Willig A. BOLD indirect vs. ASL direct measurement of muscle perfusion. J Appl Physiol 2005;99(1):376-7; author reply 377.
43. Haddar D, Haacke EM, Sehgal V, Delproposto Z, Salamon G, Seror O, et al. L'imagerie de susceptibilité magnétique : théorie et applications. J Radiol 2004;85:1901-8.
44. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999;59:5012-6.
45. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001;14:497-506.
46. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
47. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94: 1484-93.
48. Eder JP, Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84.
49. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
50. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004;233:709-15.
51. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
52. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
53. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alpha Vbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6.
54. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol 1991;113:147-54.
55. Li KC, Guccione S, Bednarski MD. Combined vascular targeted imaging and therapy: a paradigm for personalized treatment. J Cell Biochem Suppl 2002;39:65-71.
56. Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002;17:233-45.
57. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.